Globus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Globus Medical has a “Moderate Buy” consensus rating from 17 analysts, with nine buys, three strong buys, and five holds. The average 12-month price target is $101.77, above the reported opening price of $78.13.
• The company exceeded quarterly expectations, reporting EPS of $1.34 versus the $1.10 consensus and revenue of $789.61 million. Revenue increased 5.9% year over year, while analysts expect approximately $4.99 in full-year EPS.
• Institutional investors own 95.16% of the shares, with several funds increasing their positions. However, director Stephen Zarrilli sold 25,000 shares at an average price of $87.04, reducing his direct holdings by half.

Globus Medical, Inc. (NYSE:GMED - Get Free Report) has received a consensus rating of "Moderate Buy" from the seventeen ratings firms that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $101.7692.

A number of analysts have recently issued reports on the stock. UBS Group started coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They set a "neutral" rating and a $82.00 price objective on the stock. Royal Bank Of Canada decreased their target price on shares of Globus Medical from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Wells Fargo & Company dropped their price target on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a research note on Friday, August 7th. Zacks Research raised shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 10th. Finally, Truist Financial lowered their target price on Globus Medical from $115.00 to $100.00 and set a "buy" rating for the company in a research note on Thursday, July 16th.

Globus Medical Stock Performance

GMED opened at $78.13 on Friday. Globus Medical has a 1 year low of $54.15 and a 1 year high of $101.40. The firm has a 50 day moving average price of $81.02 and a 200 day moving average price of $84.37. The company has a market cap of $10.49 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 1.30 and a beta of 0.95.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same period in the previous year, the firm earned $0.86 earnings per share. Globus Medical's revenue for the quarter was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts predict that Globus Medical will post 4.99 earnings per share for the current year.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director directly owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 18.38% of the stock is owned by corporate insiders.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC grew its holdings in Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company's stock worth $1,622,000 after acquiring an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company's stock worth $320,000 after purchasing an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company's stock worth $2,228,000 after purchasing an additional 8,540 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company's stock valued at $62,000 after buying an additional 598 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company's stock valued at $25,439,000 after buying an additional 28,027 shares in the last quarter. Institutional investors own 95.16% of the company's stock.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source